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Abstract
Background: Human cord blood (hCB) is the main source of hematopoietic stem and progenitor cells (HSCs/PCs) for
transplantation. Efforts to overcome relative shortages of HSCs/PCs have led to technologies to expand HSCs/PCs ex vivo.
However, methods suitable for clinical practice have yet to be fully established.
Methodology/Principal Findings: In this study, we screened biologically active natural products for activity to promote
expansion of hCB HSCs/PCs ex vivo, and identified Garcinol, a plant-derived histone acetyltransferase (HAT) inhibitor, as a
novel stimulator of hCB HSC/PC expansion. During a 7-day culture of CD34
+CD38
– HSCs supplemented with stem cell factor
and thrombopoietin, Garcinol increased numbers of CD34
+CD38
– HSCs/PCs more than 4.5-fold and Isogarcinol, a derivative
of Garcinol, 7.4-fold. Furthermore, during a 7-day culture of CD34
+ HSCs/PCs, Garcinol expanded the number of SCID-
repopulating cells (SRCs) 2.5-fold. We also demonstrated that the capacity of Garcinol and its derivatives to expand HSCs/
PCs was closely correlated with their inhibitory effect on HAT. The Garcinol derivatives which expanded HSCs/PCs inhibited
the HAT activity and acetylation of histones, while inactive derivatives did not.
Conclusions/Significance: Our findings identify Garcinol as the first natural product acting on HSCs/PCs and suggest the
inhibition of HAT to be an alternative approach for manipulating HSCs/PCs.
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Introduction
Hematopoietic stem cells (HSCs) have been applied to the
treatment of a wide variety of blood disorders through HSC
transplantations and gene therapy [1–3]. Related as well as
unrelated human cord blood (hCB) has emerged as a source of
HSCs and the use of these cells is increasing because of the low risk
of graft-versus-host disease and facile procurement [4]. To date,
over 10,000 hCB transplantations have been conducted [5].
However, the widespread application of hCB is limited by
relatively low numbers of HSCs, resulting in a significant delay
in hematopoietic recovery and increased transplant-related
mortality. Thus approaches that can overcome low cell doses
and delayed engraftment are of great interest. The cotransplanta-
tion of two CB units from different donors, which increases the
available cell dose, has been used. Alternatively, numerous
attempts have been made to expand hCB HSCs ex vivo [6–11].
The majority of cell culture systems have exploited protein-factor
mixtures, including stem cell factor (SCF), thrombopoietin (TPO),
fms-like tyrosine kinase 3 ligand (FL), a complex of interleukin 6
(IL-6) and soluble IL-6 receptor (IL-6/sIL-6R), the Notch ligand
Delta1, Angiopoietin-like proteins, and Pleiotrophin. Notably,
Delaney and colleagues reported that transplantation with Notch-
mediated expansion ex vivo resulted in faster neutrophil engraft-
ment compared to a control group receiving uncultured hCB [8].
However, additional clinical studies will be required to confirm the
enhanced kinetics of engraftment in humans, and identification of
the cell signaling that governs the self-renewal of HSCs is needed
to improve existing methods of hCB HSC expansion ex vivo.I t
could also be pointed out that protein-factor combinations have
proven to be neither cost-effective nor readily available.
Small-molecule compounds (SMCs), which comprise natural
and chemically synthesized products, have played a pivotal role in
molecular biology and pharmaceutical therapy. The use of SMCs
has also facilitated elucidation of the signaling pathways that
control stemness and been applied to HSC expansion ex vivo [12–
16]. The method using tetraethylenepentamine, a synthetic copper
chelator, which expands hCB CD34
+ cells and increases their
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24298potential for engraftment in immunodeficient mice, has shown
feasibility in a Phase I/II study [15]. Boitano and colleagues
reported that a chemically synthesized purine derivative induced
hCB HSC expansion in culture by antagonizing the aryl
hydrocarbon receptor [16]. We also reported that activation of
the human thrombopoietin receptor by a small-molecule agonist
promoted expansion of hCB HSCs [17]. Nonetheless, there is a
need to identify more efficient SMCs and to design better
compounds in terms of efficacy and safety for clinical use.
Here, in a search for biologically active natural products that
may activate signals required for HSC expansion, we screened
natural products for effects on hCB CD34
+CD38
– cells, which are
reported to be primitive hematopoietic stem and progenitor cells
(HSCs/PCs) [18,19]. We found that Garcinol, a benzophenone
derivative originally isolated from Garcinia indica [20,21],
expands HSCs/PCs through an inhibitory effect on HAT. This
is the first report of a small-molecule HAT inhibitor promoting
HSC expansion ex vivo.
Results
Garcinol and its derivative expand human hematopoietic
progenitors
To identify biologically-active natural products that act on
HSCs/PCs ex vivo, we cultured hCB CD34
+ HSCs/PCs with
natural products in the presence of stem cell factor (SCF) and
thrombopoietin (TPO) for 7 days and examined the number of
CD34
+CD38
- HSCs in culture (Figure 1A). We screened 92
biologically-active natural products collected from commercially
available compounds (Table S1), and identified Garcinol (GAR) as
one of the most active compounds (Figure 1B and C). To evaluate
the function of GAR in detail and estimate the structure-activity
relationship, we synthesized its derivatives, Isogarcinol (ISO), O-
monomethylisogarcinol (MMI), and O-dimethylisogarcinol (DMI)
(Figure 1B). We then cultured hCB CD34
+ cells in medium
supplemented with SCF, TPO and the Garcinol derivatives for 7
days. GAR, ISO, and MMI facilitated the expansion of
CD34
+CD38
– cells compared with the DMSO control
(Figure 2A), but little affected the total cell numbers at their
effective concentrations (10 mM of GAR: 109.7610.3%, 5 mMo f
ISO: 71.56 23.7%, 2 mM of MMI: 91.16 2.5%, 0.5 mM of DMI:
93.064.1% relative to the blank control). We observed a more
efficient effect by GAR, ISO, and MMI when hCB CD34
+CD38
–
cells were used as the starting material (Figure 2B). During the 7-
day culture, CD34
+CD38
- cells expanded in number 4.5, 7.4, 2.2,
and 1.4-fold with GAR, ISO, MMI, and DMI, respectively, as
compared with the blank culture. These results indicated that
GAR derivatives other than DMI increased the number of
primitive CD34
+CD38
- cells efficiently in culture.
To evaluate the number of functional HSCs/HPCs in cultures
with GAR derivatives, we next performed colony assays. Cultured
cells with GAR derivatives contained all types of myeloid progenitors,
and there was no significant difference in total colony number
between the culture with GAR derivatives and blank. In contrast,
high proliferative potential colony-forming cells (HPP-CFCs), which
give rise to colonies with a diameter greater than 1 mm, [22] and
colony-forming units-granulocyte/erythrocyte/macrophage/mega-
karyocyte (CFU-GEMM), which represent the most primitive
progenitors, were more frequently contained in the cultures with
GAR, ISO, and MMI than those with DMSO (Figure 2C). As with
the effect on CD34
+CD38
- cell proliferation in culture, DMI showed
no activity to expand HPP-CFC and CFU-GEMM numbers
(Figure 2A-C). In all combinations of cytokines tested, the addition
of GAR further increased the numbers of CD34
+ and CD34
+CD38
-
cells compared to each blank control, even in the presence of SCF,
TPO, and FL, the most potent cytokine combination tested
(Figure 2D). These results showed that GAR derivatives other than
DMI had the positive effect on the primitive hematopoietic
progenitor proliferation during the 7-day culture.
GAR-treated CD34
+ cells include increased numbers of
SRCs
To evaluate the number of functional HSCs in cultures with
GAR, we performed a NOD/SCID-repopulation assay [19,23] to
estimate the capacity for reconstitution among the progeny of hCB
CD34
+ cells cultured with GAR in addition to SCF, TPO, and FL.
We used limiting numbers of cells for the repopulation assay to
estimate the SRC frequencies. Increasing numbers (5610
3,1 610
4,
2610
4) of fresh CD34
+ cells or 7-day cultured cells corresponding
to the same number of input CD34
+ cells were transplanted into
NOD/SCID mice. The average repopulation levels by human
hematopoietic CD45
+ cells were higher in recipient mice infused
with GAR-treated cells than in those infused with fresh CD34
+
cells or vehicle (DMSO)-treated cells (Fig. 3A). The frequency for
SRCs was 1 in 10,921 (95% confidence interval of 1 of 14,109 to 1
of 8,453) among fresh CD34
+ cells and 1 in 9,521 (95% confidence
interval of 1 of 12,318 to 1 of 7,358) in the culture with vehicle
(DMSO). In contrast, the frequency for SRCs in the culture with
GAR was 1 in 4,328 (95% confidence interval of 1 of 5,844 to 1 of
3,206), which was 2.5-fold higher than for fresh CD34
+ cells
(p=0.019) and 2.2-fold higher than for the vehicle cultures
(p=0.046) (Fig. 3B). These results demonstrated that GAR
promoted the expansion of SRCs in culture.
Ithasbeenreportedthatexpressionofhomingreceptorsiscritical
for hCB SRCs to efficiently engraft bone marrow (BM) [24].
Therefore, we evaluated the levels of surface CD184 (CXCR4) and
CD62L (L-selectin) on CD34
+ cells cultured for 7 days with or
without GAR in the presence of SCF, TPO, and FL. As compared
with the blank culture, the expression levels of homing receptors on
GAR-treated CD34
+ cells were comparable or slightly decreased;
the population of CD34
+CD184
+ cells was 1.660.3% [mean
fluorescence intensity (MFI); 35.5] and 1.060.2% (MFI; 38.2) in
control and GAR cultures, respectively, and the population of
CD34
+CD62L
+ cells was 3.760.6% (MFI; 28.5) and 3.160.2%
(MFI; 26.8) in control and GAR cultures, respectively (n=3). These
data indicated that the enhanced engraftment by GAR-treated
CD34
+ cells is attributed to an increase in SRC number rather than
augmented homing capacity during culture.
GAR inhibits HAT activity and protein acetylation
GAR has been characterized as a non-specific HAT inhibitor
and its derivative, ISO, was demonstrated to inhibit both p300 and
PCAF [21]. To confirm the reported effect of GAR derivatives on
intracellular HAT activity, we observed HAT activity in cells
treated with GAR derivatives. Indeed, treatment of cells with
GAR, ISO, and MMI, but not DMI, inhibited cellular HAT
activity in HL60 cells (Figure 4A). The inhibitory effect of GAR
and its derivatives on HAT correlated well with their capacity to
expand HSCs/PCs ex vivo. GAR also inhibited HAT activity in
hCB CD34
+ cells (Figure 4B). Next, we observed the level of
protein acetylation, which is regulated by HATs, in cells treated
with GAR derivatives. In accordance with the result of HAT
inhibition, GAR, ISO, and MMI, but not DMI, reduced cellular
histone acetylation levels in HeLa cells (Figure 4C). A reduced
level of acetylation was also observed in hCB CD34
+ cells treated
with GAR (Figure 4D). As with histone acetylation, GAR reduced
the level of acetylation of p53 at K382 in RPMI8226 cells
(Figure 4E).
Expansion of HSCs by a HAT Inhibitor
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To understand the molecular mechanisms by which GAR
promotes the expansion of HSCs, we examined global transcrip-
tion levels of genes in cultured CD34
+CD38
– cells with GAR using
a DNA microarray. Treatment of HSCs/PCs with GAR for 7
days led to the up-regulation of 20 genes and down-regulation of 9
genes in CD34
+CD38
– cells (Table 1). Among them, we validated
the expression of 6 genes by using real-time quantitative PCR
(Figure 5). Treatment of HSCs/PCs with GAR resulted in a 1.98,
1.67, and 3.44-fold increase in AMICA1, BTG2 and HLF
expression, respectively, and a 0.61, 0.43, and 0.33-fold decrease
in IL8, PF4, and PPBP expression, respectively, in the
CD34
+CD38
– cell fraction. In contrast, DMI did not significantly
change the expression of these genes, except for IL8. The
transcriptional levels of other genes reported to be implicated in
the self-renewal of HSCs, for example, HOXB4, BMI1, GATA2,
NOTCH1, p21, p27, c-MYC, EGR, and EVI-1 [25,26], were not
changed by GAR (data not shown).
Discussion
A search for biologically active natural products that promote
HSC expansion uncovered GAR, a benzophenone derivative
Figure 1. Identification of Garcinol as a natural product biologically active on HSCs/PCs. A. Experimental design for the screening of
natural compounds acting on HSCs/PCs. B. Chemical structure of Garcinol and its derivatives. C. Garcinol expands CD34
+CD38
– cell numbers. hCB
CD34
+ cells were cultured in StemSpan SFEM medium with Garcinol or the same volume of DMSO (blank) in the presence of 20 ng/mL of hrTPO and
100 ng/mL of hrSCF. At day 7 of culture, the cells were analyzed by FACS for CD34 and CD38 expression (left panel). The numbers of CD34
+CD38
–
cells relative to the blank are indicated [mean6standard error of the mean (SEM), n=3]. *p,0.05.
doi:10.1371/journal.pone.0024298.g001
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plant-derived natural product found to act on HSCs/PCs.
Isogarcinol, a derivative of GAR, was even more active, further
supporting the efficacy of GAR. As reported before, GAR
exerted its activity as a HAT inhibitor in HSCs/PCs. GAR
reduced cellular HAT activity and the levels of histone
a c e t y l a t i o ni nh C BC D 3 4
+ cells. Importantly, the inhibitory
effect of GAR and its derivatives on HAT correlated well with
their capacity to expand HSCs/PCs ex vivo.T o g e t h e r ,o u r
findings provide the first evidence of the effectiveness of
inhibiting HAT on the expansion of HSCs/PCs. GAR also
reduced the level of acetylation of p53 at K382 in RPMI8226
cells, although its effect was not obvious in hCB CD34
+ cells
(data not shown). p53 restricts the self-renewal of HSCs: p53-
deficient mice have been reported to contain twice as many
HSCs and their HSCs exhibit greater repopulating capacity
than do wild-type HSCs [27]. p300 HAT is reported to
acetylate p53 at K382, and, by doing so, enhances the sequence-
specific DNA binding of p53 [28]. Thus, GAR might expand
HSCs/PCs, at least partly, through suppression of p53 activity.
Figure 2. Garcinol efficiently expands numbers of human CD34
+CD38
– cells and colony-forming cells. A. The effects of Garcinol
derivatives on hCB CD34
+ HSCs/PCs. hCB CD34
+ cells were cultured in StemSpan SFEM medium with Garcinol derivatives or the same volume of
DMSO (blank) in the presence of 20 ng/mL of hrTPO and 100 ng/mL of hrSCF for 7 days. Cultured cells were counted with a hemocytometer (trypan
blue exclusion) and analyzed by FACS for CD34 and CD38 expression. The numbers of CD34
+CD38
– cells relative to the blank are indicated
(mean6SEM, n=3). *p,0.05. B. The effects of Garcinol derivatives on hCB CD34
+CD38
– HSCs. CD34
+CD38
– cells were isolated from hCB cells by
FACSAria and cultured as in A. Bars represent the fold-increase in the number of CD34
+CD38
– cells in the 7-day cultures compared with the initial
number of CD34
+CD38
– cells (mean6SEM, n=3). *p,0.05. C. The effects of Garcinol derivatives on colony-forming cells. The 7-day cultures of hCB
CD34
+ cells treated with Garcinol derivatives or the same volume of DMSO (blank) were plated in Methocult GF H4435 methylcellulose medium (500
cells/plate), and colonies were counted after 12 days. Bars represent the number of colony-forming units in culture (CFU-C) and HPP-CFCs per 500
cultured cells (mean6SEM, n=3). *p,0.05. D. The effects of Garcinol derivatives on HSCs/PCs in the presence of multiple cytokines. hCB CD34
+ cells
were cultured with Garcinol (10 mM) or the same volume of DMSO (blank) in the presence of SCF (100 ng/mL) alone, SCF and TPO (20 ng/mL), or SCF,
TPO, and FL (50 ng/mL) for 7 days. The numbers of CD34
+CD38
– cells relative to that in the control culture supplemented with SCF only are indicated
(mean6SEM, n=3). The number of CD34
+CD38
– cells in the control culture was arbitrarily set to 1. *p,0.05.
doi:10.1371/journal.pone.0024298.g002
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manipulation of HSCs/PCs by inhibiting components of the
epigenetic machinery. Araki et al. proposed that the treatment of
hCB HSCs with a DNA methyltransferase inhibitor, 5-aza-29-
deoxycytidine, followed by a histone deacetylase (HDAC)
inhibitor, trichostatin A, efficiently expands HSCs [29,30].
However, inhibitors for DNA methyltransferases or HDACs are
also effective against cancer cells and restrict their tumorigenic
activity by releasing the transcriptional repression of tumor
suppressor genes [31]. So, their efficacy in normal HSCs/PCs
might need further evaluation. By contrast, we previously reported
that forced expression of Bmi1, one of the polycomb-group genes,
augments stem cell activity [32]. The polycomb-group proteins
transcriptionally repress tumor suppressor genes by adding
repressive histone modifications, the trimethylation of histone
H3 at lysine 27 and monoubiquitylation of histone H2A at lysine
119, to their promoters [33,34]. Forced expression of Bmi1
reinforces the transcriptionally repressive state of tumor suppressor
genes, such as Ink4a and Arf. We speculate that GAR acts in a
similar fashion to Bmi1 by inhibiting the activity of HATs.
Correspondingly, not many genes were altered in their expression
by GAR. Given the broad effects of GAR on cellular acetylation
levels, the limited effect on gene expression was unexpected, but
may suggest a specific function of GAR in maintenance of the
transcriptionally repressive state of tumor suppressor genes.
Nevertheless, the up-regulated gene expression of hepatic
leukemia factor (HLF), a member of the proline and acidic-rich
protein family, is intriguing because HLF has been implicated in
the control of human HSC function: Forced expression of HLF in
human HSCs reportedly protects against apoptosis and enhances
in vivo reconstitution [35].
In summary, GAR and its derivatives modulate the acetylation
of not only histones but also key HSC regulators such as p53 to
establish a gene expression profile and molecular functions
Figure 3. Garcinol efficiently expands SRC numbers. A. hCB CD34
+ cells were cultured with 10 mM of GAR in the presence of rhSCF, rhTPO and
rhFL for 7 days. NOD/SCID mice (n=91) were injected with increasingly higher doses (5610
3,1 610
4,2 610
4 cells/mice) of freshly isolated hCB CD34
+
cells, cells cultured with DMSO (blank), or cells cultured with GAR, and the chimerism of human CD45
+ cells in the recipient BM cells was analyzed 8
weeks after transplantation. Bars represent the mean values of chimerism. B. Mice with at least 1% human CD45
+ cells in BM in A were considered
successfully engrafted and the frequency of SRCs was determined with L-Calc software (StemCell Technologies).
doi:10.1371/journal.pone.0024298.g003
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represents a new approach to HSC manipulation and therapy. It is
important to find out more potent, specific, and less toxic HAT
inhibitors to precisely revalidate their effectiveness on HSCs/PCs
and apply them to the manipulation of HSCs/PCs ex vivo.
Commercially available HAT inhibitors, curcumin [36] and
anacardic acid [37], were toxic and less active on HSCs/PCs
compared with GAR (data not shown). Additional screening of
HAT inhibitors might be required to obtain suitable compounds
for the expansion of HSCs/PCs ex vivo. Of interest, GAR did not
have any antagonistic function against aryl hydrocarbon, and thus
exerted an additive effect on the expansion of HSCs/PCs in
combination with SR-1, an antagonist of aryl hydrocarbon
receptor [16] (data not shown). These findings suggest that the
combination of SMCs with different molecular targets would
improve the efficacy of HSC/PC expansion ex vivo.
Materials and Methods
Ethics Statement
All experiments using the mice were performed in accordance
with our institutional guidelines for the use of laboratory animals
Figure 4. Garcinol inhibits histone acetyltransferase activity. A. Garcinol functions as an inhibitor of HAT. Nuclear extracts from HL60 cells
(1610
6) cultured with the indicated concentrations of Garcinol derivatives or the same volume of DMSO (blank) for 24 h were assayed for HAT
activity. Bars represent the relative activity of HAT (mean6SEM, n=325). *p,0.05. B. Garcinol inhibits the HAT activity of hCB CD34
+ cells. hCB CD34
+
cells (5610
5) were cultured with 10 mM of GAR or the same volume of DMSO (blank) in the presence of 20 ng/mL of hrTPO and 100 ng/mL of hrSCF
for 3 days, and the nuclear extracts of cultured cells were assayed for HAT activity. Bars represent the relative activity of HAT (mean6SEM, n=5).
*p,0.05. C. Garcinol reduces the levels of histone acetylation. HeLa cells (2610
4) were cultured with 10 mM of Garcinol derivatives or the same
volume of DMSO (blank) for 24 h. The levels of histone acetylation in the cultured cells were measured by using an EpiQuik HAT activity/inhibition
assay kit. Bars represent the levels of acetylated histones relative to the blank (mean6SEM, n=3). *p,0.05. D. Garcinol reduces the levels of histone
acetylation in hCB CD34
+ cells. hCB CD34
+ cells (5610
5) were cultured with 10 or 20 mM of GAR or the same volume of DMSO (blank) for 3 days. The
cultured cells were fixed and permeabilized and then stained with Alexa Fluor 488-conjugated anti-acetylated histone H3 antibody. Flow cytometric
analysis was performed to measure the levels of histone acetylation. Data are representative of 3 independent experiments. E. Garcinol inhibits
acetylation of p53 at K382. RPMI8226 cells (1610
6) were cultured with 10 or 20 mM of GAR or the same volume of DMSO (blank) for 1 day. The levels
of acetylation of p53 at K382 were measured by using Alexa Fluor 647-conjugated mouse anti-p53/acK382 antibody. Data are representative of 3
independent experiments.
doi:10.1371/journal.pone.0024298.g004
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Chiba University (approval ID: 21–150). The study using hCB
cells was approved by the institutional ethics committees of Chiba
University (approval ID: 692).
Reagents
Natural products and chemical derivatives for screening were
collected from the library LOPAC
1280 (Sigma-Aldrich, Missouri)
or purchased from Cosmo Bio (Tokyo, Japan). GAR was obtained
from Enzo Life Sciences (New York, USA) and its derivatives were
chemically synthesized as reported previously [21]. Briefly, GAR
was stirred for 10 hours in toluene and hydrochloric acid at room
temperature, and left for 17 hours at 4uC. The reaction mixture
was then filtered, and the residue was washed with distilled water
and acetonitrile. Isogarcinol (ISO) was finally obtained by
recrystallization in acetonitrile. ISO was then methylated by
addition of potassium carbonate and methyl iodide for 17 hours at
25uC. The product was extracted with ethyl acetate and
concentrated. O-monomethylisogarcinol (MMI) and O-dimethy-
lisogarcinol (DMI) were separated by silica gel column chroma-
Table 1. Gene expression changes in GAR-treated cells.
Symbol Gene Fold-change
ADRB1 adrenergic, beta-1-, receptor 2.6
AMICA1 adhesion molecule, interacts with CXADR antigen1 1.5
BTG2 BTG family, member2 1.8
CNTNAP5 contactin associated protein-like5 7.3
COL5A1 collagen, type V, alpha 1 1.6
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 1.9
FAM55C family with sequence similarity 55, member C 2.2
FBXL17 F-box and leucine-rich repeat protein 17 1.7
HLF hepatic leukemia factor 3.1
IGJ immunoglobulin J polypeptide 3.0
JAG2 jagged 2 1.9
LRBA LPS-responsive vesicle trafficking, beach and anchor containing 2.7
NUPL1 nucleoporin like 1 3.2
PTK2 PTK2 protein tyrosine kinase 2 2.2
SEMA3C sema domain, immunoglobulin domain (Ig) 2.3
SLC41A2 solute carrier family 41, member 2 3.2
THAP9 THAP domain containing 9 2.0
TRIM59 tripartite motif-containing 59 1.6
ZNF407 zinc finger protein 407 6.3
ZNF623 zinc finger protein 623 2.1
CST7 cystatin F (leukocystatin) 0.7
HBD hemoglobin, delta 0.6
IL8 interleukin 8 0.7
INPP5F inositol polyphosphate-5-phosphatase F 0.7
PF4 platelet factor 4 0.6
PPBP pro-platelet basic protein 0.6
RPS2 ribosomal protein S2 0.6
TP73 tumor protein p73 0.6
TP53I11 tumor protein p53 inducible protein 11 0.4
The gene expression analysis was performed using total RNA of CD34
+CD38
– cells sorted from 7-day cultures of hCB CD34
+ cells with 10 mM of GAR, 0.5 mM of DMI, or
the same volume of DMSO (blank). The DNA microarray assay was conducted with a GeneChip 39expression array (Kurabo, Osaka, Japan). The genes whose expression
was up-regulated greater than 1.5-fold or down-regulated less than 0.7-fold upon treatment with GAR compared to the blank control are shown.
doi:10.1371/journal.pone.0024298.t001
Figure 5. Treatment of GAR modifies the gene expression in
CD34
+CD38
– cells. hCB CD34
+ cells were cultured with 10 mM of GAR
or 0.5 mM of DMI in the presence of rhSCF, rhTPO and rhFL for 7 days.
Bars represent the mean of fold-changes in gene expression relative to
the blank (n=325) detected by quantitative real-time PCR. The
peptidylprolyl isomerase A or beta-2-microglobulin gene was used as
an internal control.
doi:10.1371/journal.pone.0024298.g005
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Mice
Nonobese diabetic/severe combined immunodeficient (NOD/
SCID) mice were purchased from CLEA Japan (Tokyo, Japan).
Cell culture
Human cord blood (hCB) CD34
+ cells were purchased from
Lonza (Basel, Switzerland) or purified from hCB obtained from
the Tokyo Cord Blood Bank (Tokyo, Japan). Mononuclear cells
were separated by density gradient centrifugation. CD34
+ cells
were immunomagnetically enriched using a magnetic-activated
cell sorting CD34 progenitor kit (Miltenyi Biotech, California).
The purity of hCB CD34
+ cells was over 95%. CD34
+CD38
– cells
were isolated by fluorescence-activated cell sorting using a BD
FACSAria (BD Bioscience, California). Purified CD34
+ and
CD34
+CD38
– cells were cryopreserved or used immediately for
experiments. hCB CD34
+ and CD34
+CD38
– cells were plated at
1610
4 cells/well in a 24-well plate precoated with 25 mg/mL of
fibronectin fragment CH-296 (Takara Shuzo, Otsu, Japan) [17]
and cultured in serum-free medium, StemSpan SFEM (Stem Cell
Technologies, Vancouver, Canada) supplemented with a 1%
penicillin-streptomycin mixture (Sigma) at 37uC in a humidified
atmosphere flushed with 5% CO2 in air. Recombinant human
(rh)SCF (Wako Pure Chemical Industries, Osaka, Japan) was
added at 100 ng/ml, rhFL (PeproTech, New Jersey) at 50 ng/mL,
and rhTPO (PeproTech) at 20 ng/mL. Garcinol derivatives were
added in the indicated amounts. Human leukemia cell lines, HL60
[38] and RPMI8226 [39], were purchased from DS Pharma
Biomedical (Osaka, Japan) and cultured in RPMI 1640 medium
(Invitrogen, California) containing 10% fetal bovine serum and a
1% penicillin-streptomycin mixture (Sigma) at 37uC under 5%
CO2 in a humidified incubator and passaged every three days.
The human epithelial carcinoma cell line HeLa was cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum and a 1% penicillin-streptomycin mixture
(Sigma).
Flow cytometry
Cultured hCB CD34
+ cells were stained with allophycocyanin
(APC)-conjugated anti-human CD34 and phycoerythrin (PE)-
conjugated anti-human CD38 antibodies (BD Pharmingen,
California). Then 1 mg/mL of propidium iodide (Sigma) was
added to exclude nonviable cells. Cells were analyzed on a BD
FACSCant II (BD Bioscience) or a JSAN desktop cell sorter (Bay
Bioscience, Kobe, Japan). For analyzing hematopoietic engraft-
ment in NOD/SCID mice, BM cells were stained with APC-
conjugated CD45 antibody (BD Pharmingen). To measure the
acetylated levels of histones and p53 protein, cultured cells were
fixed and permeabilized with a Cytofix/Cytoperm Fixation/
Permeabilization Solution Kit (BD Biosciences) and then stained
with Alexa Fluor 488-conjugated anti-acetylated histone H3
antibody (clone C5B11, Cell Signaling) and Alexa Fluor 647-
conjugated mouse anti-p53/acK382 antibody (clone L82-51, BD
Biosciences), respectively. To measure the expression levels of
homing receptors on cell surface, cultured hCB CD34
+ cells were
stained with APC-conjugated anti-human CD34, PE-conjugated
anti-human CD184 (clone 12G5. BD Pharmingen), and fluores-
cein isothiocyanate-conjugated anti-human CD62L antibodies
(clone DREG-56, BD Pharmingen) and analyzed on a JSAN
desktop cell sorter.
Colony forming assay
hCB CD34
+ cells, which were cultured with Garcinol for 7 days,
were plated in Methocult GF H4435 methylcellulose medium
containing 50 ng/mL human SCF, 10 ng/mL human granulo-
cyte-macrophage colony-stimulating factor, 10 ng/mL human IL-
3, and 3 U/mL human EPO (StemCell Technologies). After 12 to
14 days of culture, the colonies were counted under a microscope.
Histone acetylation assay
The histone acetylation activity in nuclear extracts and the
levels of acetylated lysine in test cells were evaluated using an
EpiQuik HAT activity/inhibition assay kit (Epigentek, Brooklyn,
NY) and Cellular histone acetylation assay kit (CycLex, Nagoya,
Japan), respectively.
Gene expression analysis
hCB CD34
+ cells were cultured in the presence of Garcinol
derivatives or DMSO for 7 days, and then CD34
+CD38
– cells
were isolated by cell sorting with a FACSAria (BD Bioscience).
Total RNA of the isolated cells was extracted using an RNeasy
Mini kit (Qiagen, California). Gene expression was analyzed with
a GeneChip 39expression array (Kurabo, Oosaka, Japan). All data
is MIAME compliant and that the raw data was deposited in Gene
Expression Omnibus (accession number GSE29459). The total
RNA (1 mg) was reverse-transcribed with a SuperScript one-step
RT-PCR kit (Invitrogen). Real-time PCR was carried out for 40 to
45 cycles of 1 minute at 60uC and 15 seconds at 95uC in an ABI
PRISM 7700 Sequence Detector (Applied Biosystems, CA). All
Taqman primers and probes were obtained from Applied
Biosystems.
Transplantation of hematopoietic cells into NOD/SCID
mice
NOD/SCID mice at 8–10 weeks of age were sublethally
irradiated with a dose of 2.75 Gy. Fresh and cultured hCB CD34
+
cells were injected intravenously. At 8 weeks post-transplantation,
the mice were sacrificed and bone marrow (BM) cells were
analyzed with a JSAN desktop cell sorter (Bay Bioscience) for the
presence of human CD45
+ cells. To obtain the frequency of SRCs,
assays were performed using limiting doses of test cells and the
data were analyzed using L-Calc software (StemCell Technolo-
gies).
Statistical analysis
All results are presented as the mean6standard error of the
mean (SEM). Statistical significance was analyzed with Student’s t-
test or Williams’ test. The level of significance was set at 0.05.
Supporting Information
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